medisourceasia.com

Industry News


About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Centre allots Rs 630 cr for medicinal plants cultivation covering one lakh hectares

About one lakh hectares of land will be covered under medicinal plants through direct financial assistance by the year of 2011-12 under the centrally-sponsored scheme of national mission on medicinal plants at a total outlay of Rs 630 crore.

The scheme, to be implemented through National Medicinal Plants Board, (NMPB) also proposes to cover another 80,000-100,000 hectares of land by extending incentives to farmers who may switch over from traditional crops to medicinal plants. This is apart from the one lakh hectare to be brought under medicinal plants cultivation directly.

Infrastructure for quality planting material, processing, warehousing, marketing, quality testing and certification will be promoted through cooperatives of growers, self-help groups, corporate etc. About 200 nurseries will be established both in public and private sector, for making available planting material of certified quality. The interventions are expected to generate approximately six crore man-days of employment by the year 2011-12, Board sources said.

The Cabinet Committee on Economic Affairs has recently approved the scheme worth Rs 630 crore for this purpose under the 11th Plan. The scheme will help in developing medicinal plants sector through production of raw material of quality and standardized constituents for use by the Ayush industry and as well as for exports and thereby enhance the quality and acceptability of Ayush systems of medicine and promote export of value added items for a increased share in the world market, NMPB board official said.

The Board also was given recently Rs 321.30 crore for the existing central sector scheme, to be implemented during the current Plan period. It would be spent on R&D for domestication of wild medicinal plants, development of agro-techniques and post harvest management storage and processing, besides promoting quality assurance and standardization through development of good agriculture practices (GAP), good collection practices (GAP) and good storage practices (GSP) and through development of monographs on medicinal plants.

The Board will help develop, implement and support certification mechanism for quality standards, GAP, GCP and GSP and promote sustainable harvesting protocols of medicinal plants from forest areas, and certification there of with this fund. Survey, inventorisation and documentation of endangered medicinal plants through periodic surveys and inventorisation, creation of gene banks/seed orchards to create an authentic source of seed and germ plasm for future will also be carried out with this fund.

(Ref: Chronicle Pharmabiz dated 28 July 2008)

DCGI warns illegal units making medical devices, directs to obtain licenses

With a view to ensure quality in the medical devices industry, a largely unregulated segment, the central drug administration is planning to crack the whip against the manufacturers running business without licenses.

In order to act tough in this regard and amid reports of unlawful manufacturing of devices, the Drug Controller General of India (DCGI) has already slapped a public notice asking them to obtain licenses from the State licensing authorities and get them approved by the central authority.

"It is understood that certain manufacturers still continue to manufacture devices belonging to the listed categories without obtaining the requisite manufacturing licenses from the designated authorities. This activity is considered unlawful and would attract penalty under the Drugs and Cosmetics Act," the DCGI said in a notice.

Cardiac stents, drug eluting stents, catheters, intra-ocular lenses, IV cannulae, bone cements, heart valves, scalp vein set, orthopaedic implants, and internal prosthetic replacements had been brought under the purview of Drugs and Cosmetics Act, making it mandatory to get license to manufacture for sale and distribution in the year 2005.

"The manufacture, import, sale and distribution of the above said categories of medical devices (including accessories which are implanted with the devices e.g. screws etc) is prohibited under the Act without a requisite license for import or manufacture for sale of these devices issued under the said rules," the notice said.

Meanwhile, the efforts to streamline the sector still remained stuck as the health ministry opposing the Medical Devices and Regulation Bill 2005 prepared by the DST, which aimed at creating a regulatory authority among other things. The health ministry held that it had the jurisdiction over the devices that are treated as new drugs.

It is also learnt that a core group set up by the DCGI to look into the matter, met a couple of times, but could not make much progress. However, the CII forum for medical equipments which largely represented multinationals also has been roped in to be part of the effort.

On the other hand, indigenous manufacturers seeking adequate representation in the panel have moved the authorities again to demand separate regulatory agency to supervise and monitor the medical devices sector and extend incentives to the local players.

(Ref: Chronicle Pharmabiz dated 28 July 2008)


Next
 

Other News

Gujarat To Bolster Healthcare Sector
CII To Organize Seminars On Regulation On Medical Devices
Conference Theme For Next Delhi IPC: “Regulation For Better Healthcare”
B Braun Launches Coroflex Please Drug Eluting Stent In India
HLL, IL&FS Ink Mou For An Integrated Medical Devices And Diagnostic Manufacturing Park
Govt. To Finance Center Of Excellence For Medical Textiles
Kehlescope, A Tongue Depressor For Examining The Oral Cavity, Invented By Indian Doctors
Productivity Council finds 40% SSI units shut due to enforcement of GMP norms
US FDA to establish offices in Delhi, Mumbai, Hyderabad soon
Spurious drugs bill to be moved in next session of parliament
Dr Batra's launches first tele-homeopathic clinic at Mumbai
DCGI to establish multi-level complaint redressal system to address industry grievances
GE Sensing develops Labwatch monitoring system for pharma-biotech sector
CCE Software develops two new solutions for Pharma ERP and Medical Rep Management
Welch Allyn launches FlexiPort blood pressure cuffs
US FDA revises communication regulation to drug companies on applications

Archives

Advertisement

 

 


Back | Back To Top | Previous | Next